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Pertactin (PRN) is an autotransporter protein produced by all members of the Bordetella bronchiseptica
cluster, which includes B. pertussis, B. parapertussis, and B. bronchiseptica. It is a primary component of
acellular pertussis vaccines, and anti-PRN antibody titers correlate with protection. In vitro studies have
suggested that PRN functions as an adhesin and that an RGD motif located in the center of the passenger
domain is important for this function. Two regions of PRN that contain sequence repeats (region 1 [R1] and
R2) show polymorphisms among strains and have been implicated in vaccine-driven evolution. We investigated
the role of PRN in pathogenesis using B. bronchiseptica and natural-host animal models. A prn mutant did
not differ from wild-type B. bronchiseptica in its ability to adhere to epithelial and macrophage-like cells in vitro
or to establish respiratory infection in rats but was cleared much faster than wild-type bacteria in a mouse lung
inflammation model. Unlike wild-type B. bronchiseptica, the prn mutant was unable to cause a lethal infection
in SCID-Bg mice, but, like wild-type bacteria, it was lethal for neutropenic mice. These results suggest that
PRN plays a critical role in allowing Bordetella to resist neutrophil-mediated clearance. Mutants producing
PRN proteins in which the RGD motif was replaced with RGE or in which R1 and R2 were deleted were
indistinguishable from wild-type bacteria in all assays, suggesting that these sequences do not contribute to
PRN function.
Bordetella pertussis and Bordetella bronchiseptica cause respi-
ratory infections in mammals. These two closely related bac-
terial subspecies display a high level of biochemical and
genomic similarity and produce a similar set of virulence fac-
tors that are regulated at the transcriptional level by a highly
conserved two-component signaling system called BvgAS (8,
46, 50, 65). However, they differ in symptomatic manifestations
and host ranges: B. pertussis infects only humans and causes the
acute disease whooping cough, while B. bronchiseptica has
been isolated from nearly all mammals and typically causes
chronic asymptomatic infections (41, 52). Nevertheless, some
crucial factors are functionally interchangeable, such as fila-
mentous hemagglutinin (FHA) (30) and the BvgAS signaling
system (40), suggesting that studying B. bronchiseptica can re-
veal insights into the function of B. pertussis factors and vice
versa. B. bronchiseptica and its natural-host animal models are
therefore valuable tools for exploring molecular mechanisms
of Bordetella pathogenesis.
Pertactin (PRN) is a putative Bordetella virulence factor
belonging to the autotransporter (AT) family. It was discov-
ered as a surface-localized immunogen of B. bronchiseptica in
1985 (49) and was found to have highly conserved homologs in
B. pertussis and B. parapertussis shortly thereafter (5, 38). Many
subsequent studies focused on the immunogenic and protec-
tive properties of PRN, leading to its inclusion in acellular
pertussis vaccines (34, 48), and efficacy trials have shown that
high anti-PRN antibody titers correlate with protection (6, 63).
Like all ATs, the nascent PRN polypeptide has a distinct
central passenger domain flanked by an N-terminal signal se-
quence and a C-terminal porin domain (22). The signal se-
quence directs the polypeptide into the periplasm through the
Sec system and is cleaved during translocation. The C-terminal
porin domain, conserved among classical (monomeric) ATs,
forms a channel in the outer membrane and is required for the
export of the passenger domain to the cell surface (22, 23).
Recent evidence indicates that the passenger domain of PRN
crosses the outer membrane in a C- to N-terminal direction,
with the N terminus being ultimately located distally from the
cell surface (31). On the cell surface, the passenger domain
folds into a predominantly right-handed -helix with the indi-
vidual rungs connected by loops of various lengths (14). The
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longest loop (residues 260 to 294 in PRN of B. pertussis To-
hama I and residues 257 to 296 in PRN of B. bronchiseptica
RB50), designated region 1 (R1), contains several Gly-Gly-
Xaa-Xaa-Pro (GGXXP) repeats and an Arg-Gly-Asp (RGD)
motif (45). RGD motifs have been shown to be important
integrin binding sites for several mammalian proteins (57), and
RGD motifs in some bacterial proteins, including PRN, were
reported to function similarly (27–29, 37), although recent
reports suggested otherwise (30, 66). Another loop of PRN
(residues 563 to 614 of PRN in B. pertussis Tohama I and
residues 564 to 608 of PRN in B. bronchiseptica RB50), desig-
nated region 2 (R2), is located at the C terminus of the pas-
senger domain and contains Pro-Gln-Pro (PQP) repeats (45).
Several studies have identified amino acid sequence variation
within R1 and R2 of PRN among B. pertussis and B. bronchi-
septica strains (2, 4, 44, 53, 54, 59). This information, together
with evidence suggesting that R1 and R2 are immunodominant
(21, 24, 25, 33, 61), led to the hypothesis that vaccination with
a single PRN type has resulted in the selection of strains that
produce antigenically distinct PRN proteins (i.e., that B. per-
tussis strains are undergoing vaccine-driven evolution) (4, 17,
45, 67).
Relatively few investigations have focused on PRN function.
Based on in vitro studies with B. pertussis or PRN purified from
B. pertussis, PRN was reported to function as an adhesin and
an invasin that is dependent on the RGD motif (36, 37). How-
ever, two different studies failed to reveal a role for PRN in
facilitating B. pertussis attachment to mammalian cells (15, 64).
B. bronchiseptica PRN was also reported to function as an
adhesin (13, 47). In vivo studies are limited to three reports:
Khelef et al. and Roberts et al. observed no difference between
the abilities of wild-type and pertactin-deficient B. pertussis
strains to colonize or grow in the murine respiratory tract (32,
55), while Nicholson et al. found that a B. bronchiseptica prn
mutant displayed reduced lung colonization in pigs at day 56
postinoculation (but not at earlier time points) compared with
wild-type bacteria (47). Thus, despite 25 years of study and the
commitment to include PRN in acellular pertussis vaccines,
knowledge of how PRN contributes to Bordetella pathogenesis
is rudimentary.
We report here an investigation of PRN function using B.
bronchiseptica and natural-host animal models. Our results
show that PRN, but neither its RGD motif nor R1 and R2,
plays an important role in overcoming neutrophil-mediated
clearance during the first week postinoculation.
MATERIALS AND METHODS
Bacterial strains. The bacterial strains used in this study are listed in Table 1.
B. bronchiseptica strains were maintained on Bordet-Gengou (BG) agar (BD
Biosciences, San Jose, CA) supplemented with 7.5% defibrinated sheep blood
(Mission Laboratories, Diamond Bar, CA) for 48 to 72 h at 37°C. To prepare B.
bronchiseptica cells for adherence assays and infection experiments, bacteria
TABLE 1. Strains and plasmids used in this study
Strain or plasmid Description Source or reference
Strains
E. coli
DH5 Molecular cloning strain BRL, Gaithersburg, MD
SM10pir Conjugation strain 43
B. bronchiseptica
RB50 Wild-type B. bronchiseptica 9
SP5 RB50 containing an in-frame deletion of codons 227-756 of prn 13
RBXQ7 RB50 in which codon 265 of prn was changed to encode glutamic acid instead of
aspartic acid (PRN D265E)
This study
RB545 RB50 containing deletions of codons 269-288 and 578-606 in prn (PRNR1R2) This study
SP5::pVC4 SP5 with plasmid pVC4 integrated into the chromosome as shown in Fig. 1A This study
RB50::PRN-NT-HA RB50 with plasmid pPRN-NT-HA integrated into the chromosome This study
RB545::PRN-NT-HA RB545 with plasmid pPRN-NT-HA integrated into the chromosome This study
RBXQ7::PRN-NT-HA RBXQ7 with plasmid pPRN-NT-HA integrated into the chromosome This study
RBX9 RB50 containing an in-frame deletion of codons 5-3647 in fhaB 11
RBX26 RB50 containing an in-frame deletion of codons 227-756 of prn and an in-frame
deletion of codons 5-3647 in fhaB
This study
Plasmids
pEG7 pBR322-based suicide plasmid (Apr and Gmr) 10
pSS4245 pBR322-based allelic exchange plasmid (see Fig. 1 and text) This study
pVC1 pSS4245 containing a 1-kb DNA fragment from prn with codon 265 changed to
encode glutamic acid instead of aspartic acid
This study
pCI78a pSS4245 containing a 1-kb DNA fragment from prn with codons 578-606 deleted
from the center
This study
pXQ4 pSS4245 containing a 1-kb DNA fragment from prn with codons 269-288 deleted
from the center
This study
pVC4 pEG7 containing the entire prn gene and its promoter region This study
pPRN-NT-HA pEG7 containing a 0.6-kb fragment corresponding to the 5 end of prn with
nucleotides encoding an HA epitope inserted between codons 38 and 39
(corresponding to the first and second amino acids of the mature PRN
protein following cleavage of the signal peptide)
This study
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were grown in Stainer-Scholte broth (60) at 37°C with shaking. Escherichia coli
strains were cultured on Luria-Bertani (LB) agar or in LB broth. When appro-
priate, culture media were supplemented with kanamycin (Km; 50 g/ml), strep-
tomycin (Sm; 25 g/ml), gentamicin (Gm; 20 g/ml), or ampicillin (Ap; 100
g/ml).
Construction of B. bronchiseptica prn mutants. Derivatives of plasmid pSS4245
(see Results for details) were constructed and used to generate B. bronchiseptica
prn mutants. The DNA fragments used to construct plasmids pVC1, pCI78a, and
pXQ4 (to ultimately create B. bronchiseptica strains RBXQ7 and RB545) were
generated by using a two-step, overlap PCR method (58) and cloned into
pSS4245. Each DNA fragment contained 1,000-bp DNA fragments with the
sequence conferring the mutation or deletion in the center. For the complemen-
tation of the prn mutation, we constructed plasmid pVC4, which contains the
entire prn gene and its promoter region, by plasmid rescue (10) (Fig. 1 and Table
1). To insert a hemagglutinin (HA) epitope into PRN for visualization by im-
munoblotting, we constructed plasmid pPRN-NT-HA, a pEG7 derivative con-
taining a 0.6-kb DNA fragment encompassing the 5 end of prn with nucleotides
encoding the HA epitope inserted between codons 38 and 39 of prn. When
pPRN-NT-HA integrates into the chromosome by homologous recombination in
the region 3 of the nucleotides encoding the HA epitope on the plasmid (con-
firmed by PCR), the resulting strains produce PRN containing an HA epitope
between the first and second amino acids of the mature protein (after cleavage
of the signal peptide). All plasmid constructs were confirmed by DNA sequence
analysis.
Bacterial conjugations. Matings between B. bronchiseptica strains and E. coli
strain SM10pir were conducted as described previously, with minor variations
(3). Briefly, B. bronchiseptica cells grown under Bvg-phase conditions were
coincubated with SM10pir cells carrying an allelic exchange plasmid (Table 1)
on BG agar containing 50 mM MgSO4 (Bvg-phase conditions) for 4 h. Cointe-
grants were selected and purified on BG-Sm-Km agar containing 50 mM MgSO4.
Cointegrants (confirmed by PCR) were then streaked onto BG plates without
added MgSO4 (Bvg	-phase conditions) and incubated for 2 days at 37°C, allow-
ing for the selection of bacteria that had undergone a second recombination
event and a loss of the allelic exchange plasmid. Colonies were screened for the
presence of the correct mutation (deletion or nucleotide substitution) by PCR
and DNA sequencing. To generate the complemented strain, E. coli strain
SM10pir harboring pVC4 (Table 1) was mated with the prn mutant, and
cointegrants were selected on BG agar containing Gm and Sm. The integration
of pVC4 at the correct location was confirmed by PCR.
Immunoblot analysis. Cultures grown overnight were used for all bacterial cell
preparations. Whole-cell lysates were prepared as described previously (40).
SDS-PAGE was performed according to the method of Laemmli (35) using
denaturing 8% SDS-polyacrylamide gels. Proteins separated by SDS-PAGE were
transferred onto nitrocellulose membranes (Schleicher and Schuell BioScience,
Dassel, Germany) and then probed with anti-His antibody (diluted 1:2,000)
followed by incubation with IR800-conjugated secondary antibody (diluted
1:5,000) (Rockland, Gilbertsville, PA). Antigen-antibody complexes were visu-
alized by using the Odyssey infrared imaging system (Li-Cor Biosciences, Lin-
coln, NE).
Adherence assay. Adherence assays with rat lung epithelial cells (L2; ATCC
CCL-149) and mouse alveolar macrophages (MH-S; ATCC CRL-2019) were
performed as described previously (11, 26), with minor modifications. L2 cells
were grown in Ham’s F12K nutrient mixture (Gibco, Carlsbad, CA) containing
10% fetal calf serum in standard 12-well tissue culture plates. L2 cells were used
when they reached 50 to 80% confluence. The culture medium was removed and
replaced with Stainer-Scholte broth containing 107 CFU of a tested bacterial
strain (multiplicity of infection [MOI] of 50); the plates were spun at 200 
 g for
5 min and then incubated for 5 min at 37°C. The cells were then washed four
times with Hanks’ balanced salts solution, fixed with methanol, stained with
Giemsa stain, and visualized by light microscopy. Adherence to MH-S cells was
performed similarly except that bacteria were stained and visualized by using
immunofluorescence as described previously (26). Adherence was quantified by
counting the number of bacteria associated with seven groups of mammalian
cells (5 L2 cells or 10 MH-S cells per group).
Animal experiments. (i) Rat colonization experiments. Female Wistar rats (3
to 4 weeks old) were inoculated with 1,000 CFU of Bordetella delivered in 10 l
to the external nares. Animals were euthanized at 14 and 28 days postinocula-
tion, and colonization levels in the nasal cavity and trachea were determined as
described previously (42).
(ii) Mouse lung inflammation experiments. Groups of six to eight BALB/c
mice (3 to 4 weeks old; Charles River Laboratories) were inoculated intranasally
with 5 
 105 CFU of Bordetella in a 50-l volume. At 1 h, 3 days, and 11 days
FIG. 1. Construction of prn mutants. (A) SP5, the prn mutant,
was created using allelic exchange to delete codons 227 to 756 of prn
from the RB50 chromosome. The prn mutation was complemented
with plasmid pVC4, a suicide plasmid containing the wild-type (wt) prn
gene and its entire promoter region. The integration of plasmid pVC4
in the region 5 of the deletion in SP5 (as shown) leaves the region 3
of the deletion in SP5 unaltered. RBXQ7 and RB545 were constructed
by allelic exchange using pSS4245 as described in the text. (B) pSS4245
is an allelic exchange plasmid for use in Bordetella species. The posi-
tions of antibiotic resistance genes, the I-SceI restriction endonucle-
ase-encoding gene (I-SceI CDS), the I-SceI recognition site, the ptx
promoter, transcription terminators (TrrnB), and the origin of repli-
cation (oriV) are shown. (C) Whole-cell lysates of wild-type and prn
mutants producing PRN proteins with HA epitopes at their N termini
were probed with anti-HA antibody. The position of the 75-kDa mo-
lecular mass marker is shown.
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postinoculation, three left lung lobes were recovered to enumerate bacterial
CFU (42). Data shown are the results of two independent experiments.
(iii) Infection of immunodeficient and neutropenic mice. SCID-beige mice (3
to 4 weeks old; Charles River Laboratories) were inoculated with 5 
 105 CFU
of Bordetella delivered to the external nares in a 50-l volume. Animals were
monitored daily for signs of respiratory distress and euthanized when moribund.
Neutropenic mice were obtained by intraperitoneally injecting BALB/c mice with
0.25 g cyclophosphamide per kg of body weight 4 days prior to inoculation. The
reduction of neutrophils by more than 90% was confirmed by Diff-Quick staining
of blood smears and microscopic examination. Animal protocols were approved
by the IACUC at the University of California, Santa Barbara (protocol 6-04-
601). A Student’s unpaired t test was used for statistical analyses.
RESULTS
Construction of prn mutant strains. B. bronchiseptica strain
SP5 is isogenic with B. bronchiseptica RB50 except for the
deletion of codons 227 through 756 from the prn gene (Fig.
1A) (13). For complementation experiments, we constructed
plasmid pVC4 by plasmid rescue. pVC4 contains the entire prn
gene, including its promoter, from RB50 on suicide plasmid
pEG7. The integration of pVC4 into the chromosome of SP5
by homologous recombination within the region 5 of the de-
letion in prn (confirmed by PCR) (Fig. 1A) results in a mero-
diploid containing both the wild-type and deletion prn alleles.
The organization of the region 3 of the prn deletion in the
merodiploid is the same as that in SP5, and therefore, if the
deletion mutation exerts any polar effects on downstream
genes (which is unlikely because the gene 3 of prn [cysG] is
convergently transcribed), it will also do so in the merodiploid.
To investigate the roles of the PRN RGD triplet and R1 and
R2 in pathogenesis, we constructed mutants using a newly
developed allelic exchange system. Allelic exchange plasmid
pSS4245 (Fig. 1B) contains the origin of replication from
pBR322 and does not replicate in Bordetella. The plasmid also
contains genes encoding resistance to ampicillin (bla), strepto-
mycin (Str), kanamycin (Kmr), bleomycin (bler), and tetracy-
cline (Tetr). For counterselection, pSS4245 carries a gene for
an intron-encoded restriction endonuclease, I-SceI, under the
control of the pertussis toxin (ptx) promoter (which is ex-
pressed only under Bvg	-phase conditions) and an I-SceI
cleavage site. We constructed a derivative of this plasmid con-
taining a 1-kb DNA fragment corresponding to codons 99 to
431 of PRN but with the codon for aspartic acid 265 changed
to encode glutamic acid to change the RGD in the passenger
domain of PRN to RGE. This plasmid, pVC1, was introduced
into RB50 by conjugation, and cointegrants were selected on
BG agar containing Km (to select for the plasmid), Sm (to
inhibit the growth of E. coli), and 50 mM MgSO4 (Bvg
-phase
conditions). Cointegrants were restreaked once onto the same
medium and then streaked onto BG agar without Gm or
MgSO4. Under these Bvg
	-phase conditions, the ptx promoter
is activated, the gene encoding I-SceI is expressed, and the
I-SceI that is produced cleaves at its recognition site, resulting
in a double-stranded DNA break in the chromosome. Repair
by homologous recombination between sequences that flank
the integrated plasmid results in the loss of the plasmid from
the chromosome and, if recombination occurs on the opposite
side of the lesion from where the initial recombination event
occurred, the transfer of the lesion to the chromosome. Colo-
nies that grew on BG agar were screened by PCR and DNA
sequencing to identify mutants containing the DNA changes
conferring the Asp265Glu (D265E or RGD3RGE) substitu-
tion. One strain, called RBXQ7, was used for further studies.
A similar approach was used in two successive steps to con-
struct a strain, called RB545, in which codons 269 to 288 and
578 to 606 of the prn gene, corresponding to R1 and R2,
respectively, were deleted (Fig. 1A).
To visualize the PRN proteins produced in the mutant
strains, we constructed derivatives in which nucleotides encod-
ing hemagglutinin (HA) epitopes were inserted between
codons 38 and 39 of prn. RBXQ7 (the PRN D265E mutant)
produced a PRN protein that was indistinguishable in size and
amount from that produced by RB50, and RB545 (the
R1R2 mutant) produced a slightly smaller PRN protein, as
expected (Fig. 1C). Note that pro-Prn (the passenger domain
plus the porin domain) runs with a mobility of 90 kDa and
that the passenger domain alone runs at 69 kDa. Strains that
produced PRN proteins lacking HA epitopes were used for all
subsequent experiments (growth curves, adherence assays, and
animals experiments) to avoid any possible detrimental effects
from the HA epitopes.
To determine if any of the mutations that we introduced into
B. bronchiseptica affected the growth rate, we compared the
growth rates of wild-type and mutant strains incubated in
Stainer-Scholte broth at 37°C (Bvg	-phase conditions).
Growth curves for all strains were indistinguishable (data not
shown), indicating that the mutations did not alter the ability of
B. bronchiseptica to grow in vitro under conditions in which prn
is expressed.
Pertactin does not appear to contribute to the adherence of
B. bronchiseptica to epithelial or macrophage-like cell lines.
PRN was reported previously to contribute to Bordetella ad-
herence to epithelial and/or macrophage-like cell lines (37).
We compared wild-type and mutant strains of B. bronchiseptica
for their abilities to adhere to rat lung epithelial L2 cells and
mouse macrophage-like MH-S cells. SP5, the prn mutant, was
indistinguishable from RB50 in its ability to adhere to these
cells lines (Fig. 2). A fhaB strain, RBX9, which is defective
for adherence to several cell lines (11), is shown for compari-
son. As expected, a fhaB prn double mutant strain, RBX26,
behaved similarly to the fhaB strain (Fig. 2). Therefore, PRN
is not required for B. bronchiseptica strain RB50 to adhere to
mammalian cells, at least those tested here.
PRN is not required for respiratory tract colonization in
rats. We used a rat model to determine the contribution of
PRN to the colonization of the respiratory tract. Female
Wistar rats were inoculated with 1,000 CFU of either wild-type
RB50 or the prn mutant delivered in a small volume (10 l)
to the nares. Colonization levels in tracheas and nasal septa
were determined at days 14 and 28 postinoculation. The prn
mutant was recovered at levels similar to those of RB50 at both
time points in both tissues (data not shown), indicating that prn
is not required for B. bronchiseptica to colonize the respiratory
tracts of rats.
PRN is required for B. bronchiseptica to grow and/or resist
inflammatory clearance in the lungs of mice. We have used a
mouse model to investigate the roles of specific virulence genes
in overcoming inflammation-mediated clearance in the lower
respiratory tract (18, 19, 26, 30). In this model, animals were
inoculated with 5 
 105 CFU of bacteria in 50 l. The number
of bacteria recovered from the lungs of animals inoculated with
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wild-type B. bronchiseptica typically increases to about 5 
 106
during the first 7 days of infection and then decreases slowly,
and the bacteria are eventually cleared from the lungs by about
30 days postinoculation (26). Days 3 and 11 postinoculation
have proven to be the most informative time points, especially
with regard to the ability of B. bronchiseptica to influence
and/or resist the inflammatory response (22, 26). We inocu-
lated 3- to 4-week-old female BALB/c mice with wild-type B.
bronchiseptica RB50, SP5 (the prn mutant), and SP5::pVC4
(the complemented strain) and determined the number of
CFU in the lungs at 3 and 11 days postinoculation. Additional
animals were sacrificed at 1 to 3 h postinoculation (day 0) to
confirm that similar numbers of bacteria were delivered to
each site initially (Fig. 3). The prn mutant was recovered from
the lungs in much smaller numbers than wild-type bacteria at
both 3 and 11 days postinoculation (Fig. 3). The comple-
mented strain was recovered at levels similar to those of wild-
type bacteria at all time points, indicating that the defect dis-
played by the prn strain was due specifically to the deletion of
the prn gene (Fig. 3). The gross appearance of lung tissues
recovered from all mice was healthy and no different from that
of lungs harvested from uninfected mice. These results indicate
that PRN is required for B. bronchiseptica to grow and/or resist
inflammation-mediated clearance in the lungs during the first
week postinoculation.
PRN is required for the fhaB strain to cause a bimodal or
hyperinflammatory response in mice. Intranasal inoculation of
BALB/c mice with fhaB B. bronchiseptica results in a hyper-
inflammatory response compared with inoculation with wild-
type B. bronchiseptica (26, 30). At a dose of 5 
 105 CFU, this
hyperinflammatory response leads to a rapid clearance of the
bacteria in about half of the animals and inflammation-medi-
ated pulmonary damage that allows the growth of the bacteria
to high numbers and, ultimately, death of the mice within
about 4 days in the other half of the animals (26, 30). The gross
FIG. 2. Adherence of B. bronchiseptica strains to L2 (rat lung epi-
thelial) and MH-S (murine alveolar macrophage-like) cell lines. Data
from at least two independent experiments were averaged, and the
standard deviations are shown (MOI  50). Asterisks indicate a sta-
tistically significant difference compared with RB50.
FIG. 3. Colonization of mouse lungs. Shown are data for colonization of mouse lungs at 1 to 3 h (day 0), 3 days, and 11 days postinoculation
with 5 
 105 CFU of wild-type or prn mutant strains. Each symbol indicates the number of CFU from a single animal. The horizontal bar indicates
the geometric mean. For animals inoculated with the fhaB strain, the means for the moribund animals (108 CFU) and healthy animals (106
CFU) were calculated separately. The dashed line represents the lower limit of detection. , P  0.05 compared with RB50.
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appearance of lungs recovered from moribund mice is easily
distinguishable from that of healthy animals (patches of white
and dark red with obvious signs of consolidation and infarc-
tion), while the gross appearance of lungs from healthy animals
was indistinguishable from that of uninfected mice. The mi-
croscopic appearance of hematoxylin- and eosin-stained histo-
logical sections corresponds to the macroscopic appearance:
lungs from moribund mice were filled with inflammatory cells,
predominantly neutrophils and lymphocytes, while lungs of
healthy mice show only mild inflammation (24). We reasoned
that if PRN plays a proinflammatory role, the hyperinflamma-
tion that is seen in response to infection with the fhaB strain
will not occur in animals inoculated with a prn fhaB double
mutant and that animals will not suffer inflammation-mediated
lung damage (and death), but the bacteria may grow to high
numbers in the lungs due to the lack of recruitment of inflam-
matory cells. Alternatively, if PRN plays a role specifically in
resisting inflammation-mediated clearance, a fhaB prn dou-
ble mutant will be cleared faster than the prn single mutant
due to the hyperrobust inflammatory response induced in the
absence of FHA’s immunomodulatory effects. The number of
CFU recovered from mice inoculated with 5 
 105 CFU of the
prn fhaB mutant was lower than that recovered from mice
inoculated with wild-type bacteria and the single mutants at
day 3 postinoculation, and no bacteria were recovered from
prn fhaB-inoculated mice at day 11 postinoculation (Fig. 3).
Moreover, none of the mice inoculated with the double mutant
showed any signs of respiratory distress or illness at any time
during the experiment, and all lungs that were removed from
these animals appeared healthy, with no macroscopic signs of
inflammation-mediated damage. PRN is therefore required for
the fhaB strain to cause a lethal infection (which occurs in
about half of the mice at the dose used in this model), possibly
by contributing to the ability of the bacteria to resist clearance
by inflammatory cells, which consequently causes a sustained
activation of inflammation.
Neither the RGD motif nor region 1 or region 2 is required
for PRN to contribute to defense against inflammation-medi-
ated clearance. To determine if the RGD triplet or the repeats
in regions 1 and 2 are important for PRN function in vivo, we
compared the PRN D265E mutant and the PRNR1R2 mu-
tant with wild-type B. bronchiseptica in the mouse model. The
numbers of CFU of both mutants recovered from the lungs of
inoculated mice were similar to those for wild-type bacteria at
all time points (Fig. 3), indicating that neither the RGD motif
nor regions 1 and 2 are required for B. bronchiseptica to grow
and/or resist inflammation-mediated clearance in mice.
PRN is required for B. bronchiseptica to overcome the innate
immune response. Our data indicate that PRN is important for
the growth of B. bronchiseptica in the lungs during the first
week postinoculation, suggesting that it plays a role in over-
coming inflammation-mediated clearance. To investigate this
possibility further, we used SCID-Bg mice, which lack B and T
cells and have defective NK cells and are therefore dependent
on innate immunity for protection against pathogens (12, 56).
Consistent with previous results (12, 26, 56), wild-type B. bron-
chiseptica caused a lethal systemic infection in SCID-Bg mice
(Fig. 4). In contrast, mice inoculated with the prn strain were
healthy for the duration of the experiment (Fig. 4). PRN is
therefore required for B. bronchiseptica to overcome innate
immune mechanisms that are functional in SCID-Bg mice.
PRN is required for defense of B. bronchiseptica against
neutrophils. SCID-Bg mice are at least partially dependent on
neutrophils to control bacterial infection, and neutrophils are
required for mice to control B. bronchiseptica infection (12, 19,
56). If PRN is specifically required for B. bronchiseptica to
resist neutrophil-mediated clearance, then both wild-type and
prn bacteria should cause a lethal infection in neutropenic
mice. If PRN is required to overcome a neutrophil-indepen-
dent innate immune clearance mechanism, then neutropenic
mice should be able to control infection by the prn mutant.
Mice rendered neutropenic by treatment with cyclophospha-
mide were inoculated with wild-type B. bronchiseptica or the
prn mutant and quickly succumbed to infection by both
strains (Fig. 5). Together with the results obtained with the
SCID-Bg mice, these data indicate that PRN is required for B.
bronchiseptica to resist neutrophil-mediated clearance.
DISCUSSION
Although pertactin is typically referred to as a Bordetella
adhesin, previously reported data supporting this designation
are inconclusive. Only three studies compared the abilities of
wild-type and PRN-deficient B. pertussis strains to adhere to
mammalian cells in vitro: in two of these studies, the PRN-
deficient mutants were reported to adhere less efficiently to
FIG. 4. Infection of SCID-beige mice. Groups of six mice were
infected intranasally with phosphate-buffered saline (PBS) or 500 CFU
of RB50 or SP5 and monitored for signs of disease. Shown are the
percentages of surviving mice over time.
FIG. 5. Infections of neutropenic mice. Groups of six BALB/c mice
rendered neutropenic by cyclophosphamide treatment were inoculated
with PBS or 5 
 105 CFU of either RB50 or SP5. Shown are the
percentages of surviving mice over time.
2906 INATSUKA ET AL. INFECT. IMMUN.
CHO cells, HeLa cells (37), and monocytes (20) than wild-type
bacteria, while the third study reported no difference in adher-
ence to NCI-H292 and HEp-2 cells between wild-type and
mutant bacteria (64). Those studies all used the same strain of
B. pertussis in which the prn gene was disrupted by the insertion
of a kanamycin resistance gene. Whether the contradictory
results are due to differences in the host cells used or adher-
ence assay protocols is unknown. Two studies compared wild-
type B. bronchiseptica with derivatives containing in-frame de-
letion mutations in prn for their abilities to mediate adherence:
Nicholson et al. reported that a PRN-deficient mutant was less
efficient at adhering to L2 cells and PK-15 cells than wild-type
B. bronchiseptica strain KM22 (47), and Edwards et al. ob-
served a decreased adherence of a PRN-deficient derivative of
B. bronchiseptica strain RB50 (SP5, the same strain used in our
study) to ciliated rabbit tracheal explant cells compared with
that of wild-type bacteria (13). We found no difference be-
tween the abilities of RB50 and SP5 to adhere to L2 cells and
MH-S cells. We do not know if our results differ from those of
Nicholson et al. because of differences in the bacterial strains
used or differences in adherence assay protocols. For B. bron-
chiseptica strain RB50, however, we can conclude that while
PRN may contribute to adherence to ciliated epithelial cells in
the trachea (13), it appears not to contribute to adherence to
epithelial and macrophage cell lines in vitro. Whether PRN
functions as a Bordetella “adhesin” therefore remains unre-
solved and may remain so until its host cell receptor, if one
exists, is identified.
Although it is unlikely to mimic the natural course of infec-
tion for any respiratory pathogen, the murine lung inflamma-
tion model is useful for investigating the ability of bacteria to
resist and/or overcome the innate immune responses of their
mammalian hosts. In this model, wild-type B. bronchiseptica
strain RB50 typically increases in number in the lungs by about
1 log during the first week of infection and is then gradually
cleared from the lungs over the next 30 days (19, 26, 30). The
prn mutant, in contrast, was reduced in number by 2 logs
during the first 3 days postinoculation compared with wild-type
bacteria and was maintained at that level over the next week.
The inability of the prn mutant to grow in the lungs of mice
during the first week postinoculation is similar what was pre-
viously observed for a B. bronchiseptica mutant that is unable
to produce adenylate cyclase toxin (ACT) (19). Also, similar to
the phenotype of ACT-deficient B. bronchiseptica (19), the
prn mutant was unable to cause a lethal infection in SCID-Bg
mice but was capable of causing a lethal infection in neutro-
penic mice. These results indicate that, like ACT, PRN is
required to resist neutrophil-mediated clearance. The fact that
the fhaB prn double mutant was cleared from the lungs
faster than the prn or fhaB single mutant is also consistent
with a role for PRN in resisting neutrophils. Our previous
results indicate that inoculation with FHA-deficient B. bron-
chiseptica induces a more robust inflammatory response in the
lungs of mice than does inoculation with FHA-producing B.
bronchiseptica (26, 30). Armed with ACT and PRN (as well as
other virulence factors), the fhaB mutant is able to resist
complete clearance by the hyperinflammatory response at day
11 postinoculation. Without PRN (shown here) or ACT (C. S.
Inatsuka et al., manuscript in preparation), the bacteria are
unable to resist the hyperinflammatory response and are com-
pletely cleared from the lungs by day 11. ACT was shown
previously to inhibit bactericidal activities of phagocytic cells
(7, 16, 51, 68). Our data suggest that Prn may be required for
this ability, perhaps by allowing interactions between the bac-
teria and phagocytic cells so that ACT can be efficiently deliv-
ered and/or by affecting signaling events in the host cells that
make them susceptible to ACT-mediated inhibition. We are
currently developing in vitro assays using human peripheral
blood neutrophils to explore this possibility.
Based on inhibition by RGD-containing peptides, the RGD
motif in the passenger domain of PRN was previously pro-
posed to mediate adherence to CHO cells and the invasion of
HeLa cells by B. pertussis (36, 37). Everest et al., however, who
compared strains of E. coli and Salmonella enterica serovar
Typhimurium producing wild-type PRN or a PRN RGE mu-
tant, found no evidence of a role for the PRN RGD in adher-
ence or invasion (15). Consistent with the results of Everest et
al., we found that a B. bronchiseptica strain producing a PRN
protein with a D265E substitution was indistinguishable from
wild-type B. bronchiseptica in its ability to grow and/or resist
inflammation-mediated clearance in the lungs of mice, suggest-
ing that the RGD motif at positions 263 to 265 of PRN does
not contribute to PRN function in vivo. We showed recently
that the RGD motif in the mature FHA protein was not re-
quired for B. bronchiseptica to colonize the tracheas of rats or
to modulate the inflammatory response in the lungs of mice
(30), and Waters et al. showed a few years ago that the RGD
motif of the aggregation substance was not responsible for the
interaction of Enterococcus faecalis with host cells (66). At
present, to our knowledge, there is no published report show-
ing a role for an RGD triplet in a bacterial protein in a bac-
terium-host interaction in vivo. Whether such motifs contrib-
ute to any interactions between pathogens or symbionts and
their eukaryotic hosts therefore remains undetermined.
Our study also failed to reveal a role for R1 and R2 of PRN
in the ability of B. bronchiseptica to infect rats or mice. This
result was unexpected given the plethora of reports indicating
that these regions are variable and immunogenic and that
vaccine-driven evolution is selecting for strains carrying prn
alleles that are antigenically distinct from the alleles used to
produce proteins for acellular pertussis vaccines (4, 17, 39, 45,
61, 67). If these regions are not required for PRN function but
represent important immunogenic targets, why are they main-
tained? Our study focused only on the contribution of PRN to
the establishment of colonization (in rats) and the ability to
resist inflammation-mediated clearance (in mice), and it is
possible that PRN, and domains within PRN, contributes to
other aspects of Bordetella pathogenesis, such as persistence
and circulation within immune populations.
We also report here a new allelic exchange system for use in
Bordetella. This system uses an intron-encoded restriction en-
donuclease, I-SceI, under the control of the pertussis toxin
(ptx) promoter and an I-SceI cleavage site to select for the loss
of the plasmid from cointegrants. Previous allelic exchange
systems used for B. pertussis relied on the rpsL gene, conferring
sensitivity to streptomycin, for counterselection, which re-
quired the isolation and use of streptomycin-resistant deriva-
tives of wild-type B. pertussis strains (62). The new system can
be used with wild-type B. pertussis strains, alleviating concerns
that any phenotypes displayed by the resulting mutants are due
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to the mutation conferring streptomycin sensitivity. Allelic ex-
change systems used for B. bronchiseptica relied on the Bacillus
subtilis sacB gene for counterselection (1). We and others have
observed that the frequency of obtaining B. bronchiseptica
cointegrants is much lower for a suicide plasmid containing the
sacB gene than for plasmids that do not contain the sacB gene
and that those cointegrants that are obtained are often sucrose
resistant, suggesting the selection of mutations in the sacB
gene. We obtained cointegrants of pSS4245 at a high fre-
quency, and after counterselection by growing the bacteria
under Bvg	-phase conditions, 100% of the colonies obtained
had lost the plasmid. The pSS4245 allelic exchange system is
therefore superior to those that have been used previously for
B. pertussis and B. bronchiseptica.
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